+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 80Years
All Genders
ID07182890

Evaluating Clostridium Butyricum Versus Placebo for Anxiety and Depression in Functional Dyspepsia Patients Using Standard Treatments

Led by Xijing Hospital of Digestive Diseases · Updated on 2026-10-13

180

Participants Needed

1

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating whether Clostridium butyricum can help reduce anxiety and depression symptoms in patients diagnosed with functional dyspepsia FD according to the Rome IV criteria. The study is designed as a double-blind, placebo-controlled clinical trial enrolling 180 participants, focusing on improving mental health alongside standard FD treatments. This phase 4 trial aims to provide more evidence on managing anxiety and depression in FD patients using probiotics.

CONDITIONS

Brief Title

Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia

Research Team

Y

Yongquan Shi Shi

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here